Table 3.
Laboratory findings of patients before PMX-DHP in anti-MDA-5 Ab positive and negative groups
| Positive (n = 10) | Negative (n = 4) | p value | |
|---|---|---|---|
| P/F ratio | 140.3 (48.6–242.7) | 251 (167–262.5) | 0.024* |
| APACHE II | 13 (11–17) | 11 (9–15) | 0.175 |
| HRCT score, % | 233.9 (177.0–309.6) | 238.7 (191.8–361.2) | 0.777 |
| WBC, /μL | 10,300 (3300–15,600) | 13,200 (11100–19,400) | 0.065 |
| Neut, /μL | 9527 (2670–13,603) | 12,032 (7825–17,188) | 0.258 |
| Lym, /μL | 510 (0–1310) | 1774 (214–2775) | 0.120 |
| Plt (× 104), μL | 22.6 (9.4–31.6) | 32.5 (29.7–40.7) | 0.007* |
| LDH, U/L | 466 (343–1104) | 323 (171–462) | 0.024* |
| CRP, mg/dL | 0.64 (0.13–4.52) | 2.17 (0.14–13) | 0.888 |
| KL-6, U/mL | 1849 (403–4730) | 1168 (390–2725) | 0.258 |
| SP-D, ng/mL | 71.3 (15–341) | 166.1 (116.6–339.9) | 0.090 |
| Ferritin, ng/mL | 1260.3(13–4362) | 215.9 (145.3–701.3) | 0.192 |
| HMGB-1, ng/mL | 14.6 (2.7–37.4) | 8.4 (3.6–30) | 0.374 |
Dates are expressed as group median values. The p values refer to comparisons between the survivors and non-survivors groups. *: p value <0.05
P/F, arterial partial pressure of oxygen/ fraction of inspired oxygen; WBC, white blood cells; Neut, neutrophils; Lym, lymphocytes; Plt, platelets; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; SP-D, Surfactant protein-D; HMGB-1, High-mobility group box protein 1; PMX-DHP, direct hemoperfusion therapy using a polymyxin B-immobilized fiber column; anti-MDA-5 Ab, anti-melanoma differentiation-associated gene 5 antibody